S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$62.90
0.0%
$62.67
$36.47
$63.00
$4.72B1.541.81 million shs2.74 million shs
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
$2.17
-7.3%
$2.05
$0.95
$8.95
$41.14M0.6741,451 shs33,476 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
-0.02%+0.02%+0.45%+18.14%+66.05%
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-7.34%-9.58%+13.61%-22.78%-57.46%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
1.8285 of 5 stars
0.94.01.70.02.64.21.3
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
2.9092 of 5 stars
3.54.00.00.03.31.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
1.80
Reduce$52.13-17.13% Downside
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
3.00
Buy$8.00268.66% Upside

Current Analyst Ratings

Latest PMN and MDC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/7/2024
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
1/31/2024
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ In-Line$57.00 ➝ $63.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$4.64B1.02$5.31 per share11.84$45.24 per share1.39
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
$10K4,114.32N/AN/A$0.20 per share10.85

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$401.01M$5.2811.91N/A8.64%12.32%7.34%5/7/2024 (Estimated)
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)

Latest PMN and MDC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/A-$0.09-$0.09-$0.09N/AN/A
1/30/202412/31/2023
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$1.50$1.56+$0.06$1.56$1.29 billion$1.31 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
$2.203.50%+17.73%41.67%1 Years
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/AN/AN/AN/AN/A

Latest PMN and MDC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/17/2024
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
quarterly$0.553.5%2/6/20242/7/20242/21/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
0.50
9.76
3.92
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/A
1.46
1.46

Ownership

Institutional Ownership

CompanyInstitutional Ownership
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
88.08%
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
50.13%

Insider Ownership

CompanyInsider Ownership
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
23.30%
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
10.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
M.D.C. Holdings, Inc. stock logo
MDC
M.D.C.
1,76075.05 million57.56 millionOptionable
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
618.96 million17.01 millionNot Optionable

PMN and MDC Headlines

SourceHeadline
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
globenewswire.com - April 9 at 7:00 AM
FY2024 EPS Estimates for ProMIS Neurosciences, Inc. (NASDAQ:PMN) Decreased by Leede Jones GabFY2024 EPS Estimates for ProMIS Neurosciences, Inc. (NASDAQ:PMN) Decreased by Leede Jones Gab
americanbankingnews.com - April 6 at 2:18 AM
ProMIS Neurosciences to Present in Upcoming Investor Conferences in AprilProMIS Neurosciences to Present in Upcoming Investor Conferences in April
globenewswire.com - April 4 at 7:00 AM
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
globenewswire.com - April 1 at 4:15 PM
ProMIS Neurosciences Strengthens Global Intellectual Property PortfolioProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
globenewswire.com - March 11 at 7:00 AM
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
globenewswire.com - February 22 at 7:00 AM
Researchers discover a promising compound to treat neuropathic painResearchers discover a promising compound to treat neuropathic pain
interestingengineering.com - February 4 at 12:20 AM
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein VaccineProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
finance.yahoo.com - January 22 at 8:48 AM
ProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership TransitionProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership Transition
finanznachrichten.de - January 3 at 9:13 AM
BTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)BTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)
markets.businessinsider.com - January 3 at 9:13 AM
ProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive OfficerProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive Officer
markets.businessinsider.com - January 3 at 9:13 AM
ProMIS Neurosciences, Inc. Announces Leadership TransitionProMIS Neurosciences, Inc. Announces Leadership Transition
finance.yahoo.com - January 3 at 9:13 AM
ProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14ProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14
msn.com - November 14 at 7:10 PM
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - September 6 at 3:28 PM
ProMIS Neurosciences Inc. [PMN] Investment Appeal on the RiseProMIS Neurosciences Inc. [PMN] Investment Appeal on the Rise
knoxdaily.com - August 23 at 4:58 PM
ProMIS Neurosciences scales 31% on $20.4M private placementProMIS Neurosciences scales 31% on $20.4M private placement
msn.com - August 22 at 7:40 AM
ProMIS Neurosciences Announces $20.4 Million Private Placement FinancingProMIS Neurosciences Announces $20.4 Million Private Placement Financing
finance.yahoo.com - August 21 at 4:38 PM
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
finance.yahoo.com - May 15 at 6:49 PM
Closing Bell: Promis Neurosciences Inc down on Friday (PMN)Closing Bell: Promis Neurosciences Inc down on Friday (PMN)
theglobeandmail.com - May 6 at 8:15 AM
Closing Bell: Promis Neurosciences Inc up on Thursday (PMN)Closing Bell: Promis Neurosciences Inc up on Thursday (PMN)
theglobeandmail.com - April 27 at 10:10 PM
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s DiseaseData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
finance.yahoo.com - April 25 at 5:52 PM
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual MeetingProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
finance.yahoo.com - April 24 at 8:50 AM
Closing Bell: Promis Neurosciences Inc up on Tuesday (PMN)Closing Bell: Promis Neurosciences Inc up on Tuesday (PMN)
theglobeandmail.com - April 19 at 1:59 AM
Closing Bell: Promis Neurosciences Inc down on Monday (PMN)Closing Bell: Promis Neurosciences Inc down on Monday (PMN)
theglobeandmail.com - April 18 at 3:38 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

M.D.C. logo

M.D.C.

NYSE:MDC
M.D.C. Holdings, Inc., through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name. The company conducts its homebuilding operations in Arizona, California, Nevada, New Mexico, Oregon, Texas, Washington, Colorado, Idaho, Utah, Alabama, Florida, Maryland, Pennsylvania, Tennessee, and Virginia. Its financial services operations comprise originating mortgage loans primarily for homebuyers; providing insurance coverage primarily to its homebuilding subsidiaries and subcontractors for homes sold by its homebuilding subsidiaries, and for work performed in completed subdivisions; acting as a re-insurer on the claims; selling third-party personal property and casualty insurance products to homebuyers; and offering title agency services to homebuilding subsidiaries and customers in Colorado, Florida, Maryland, Nevada, Pennsylvania, and Virginia. The company was founded in 1972 and is headquartered in Denver, Colorado.
ProMIS Neurosciences logo

ProMIS Neurosciences

NASDAQ:PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.